CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, president and CEO of BioVie, who will discuss bezisterim (NE3107), the company’s first-in-class, orally available small molecule that targets in ...

Core Viewpoint - BioVie Inc. has successfully closed a public offering of 6,000,000 units, raising approximately $12 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - Each unit in the offering consisted of one share of common stock and one warrant, priced at $2.00 per unit [1]. - The underwriter exercised an option to purchase an additional 667,300 warrants, increasing the total offering size [1]. - The warrants are immediately exercisable at an exercise price of $2.50 per share and expire five years from issuance [1]. Group 2: Use of Proceeds - The proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for chronic debilitating conditions, including neurological disorders like Alzheimer's and Parkinson's diseases, as well as liver disease [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in neurodegenerative diseases [5]. - BioVie’s orphan drug candidate BIV201 is under evaluation for treating liver cirrhosis and ascites, with FDA Fast Track status [5].